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Mitochondrial fusion and fission is a dynamic process critical for the maintenance of 
mitochondrial function and cell viability.  During excitotoxicity neuronal mitochondria 
are fragmented but the mechanism underlying this process is poorly understood.  Here 
we show that Mfn2 is the only member of the mitochondrial fusion/fission machinery 
whose expression is reduced in in vitro and in vivo models of excitotoxicity. Whereas in 
cortical primary cultures Drp1 recruitment to mitochondria plays a primordial role in 
mitochondrial fragmentation in an early phase that can be reversed once the insult has 
ceased, Mfn2 downregulation intervenes in a delayed mitochondrial fragmentation 
phase that progresses even when the insult has ceased. Downregulation of Mfn2 causes 
mitochondrial dysfunction, altered calcium homeostasis and enhanced Bax translocation 
to mitochondria, resulting in delayed neuronal death. We found that transcription factor 
MEF2 regulates basal Mfn2 expression in neurons, and that excitotoxicity-dependent 
degradation of MEF2 causes Mfn2 downregulation. Thus, Mfn2 reduction is a late 
event in excitotoxicity and its targeting may help to reduce excitotoxic damage and 
increase the currently short therapeutic window in stroke.   









Glutamate is the main excitatory neurotransmitter in the central nervous system. It plays 
an essential role in development, synaptic plasticity and neuronal survival but sustained 
elevated levels of extracellular glutamate kill neurons in a process called excitotoxicity 
(Arundine & Tymianski, 2003). Excitotoxicity takes place in both chronic neurological 
diseases, such as Huntington’s and Alzheimer’s disease, and in acute episodes such as 
traumatic brain injury and ischemic stroke.   The NMDA receptor (NMDAR) is the 
main ionotropic glutamate receptor in the CNS and the excessive flux of Ca
2+
 that 
passes through it is a major cause of excitotoxicity. Despite evidence indicating a 
crucial role of NMDAR activation in brain damage during stroke, clinical trials with 
NMDAR blockers have failed because of poor tolerance and efficacy (Ikonomidou & 
Turski, 2002; Muir, 2006). In contrast to excessive NMDAR activity that causes cell 
death, its physiological activity triggers pro-survival signals that may play a role in 
promoting recovery and preventing delayed neuronal loss in the penumbra (Ikonomidou 
& Turski, 2002; Lo, 2008). Thus, future therapies to reduce excitotoxicity must target 
pro-death events downstream of NMDAR without affecting the pro-survival signals.  
Several mechanisms are implicated in cell death triggered by Ca
2+
 influx through 
NMDAR.  Mitochondrial dysfunction caused by excessive Ca
2+
 uptake acts as a 
signaling hub for many pro-death events (Almeida et al, 1999; Reynolds & Hastings, 
1995; Soriano et al, 2008; Stout et al, 1998; Yu et al, 2002).   
Mitochondria are dynamic organelles that constantly fuse and divide, changing shape 
and localization. The equilibrium between fission and fusion is important for 
mitochondrial function, which is not only limited to supplying energy to the cell, but 





 homeostasis, and is a key regulator of cell death progression.  The core 
mitochondrial fusion and fission machineries are formed by a group of dynamin-related 
large GTPases (Liesa et al, 2009; Westermann, 2010).  
Inner mitochondrial membrane fusion is mediated by Opa1. Two Mitofusins (Mfn), 
Mfn1 and 2, mediate mitochondrial outer membrane fusion. Mfn1 and Mfn2 display 
high homology (81%) and around 60% identity, but nonetheless they have non-
redundant roles (de Brito & Scorrano, 2008b; Liesa et al, 2009). In addition to its fusion 
role Mfn2 localization in the ER is necessary to maintain the reticular morphology of 
the ER and control the ER–mitochondria interaction (de Brito & Scorrano, 2008a).  
Mfn2 may also play a role in neuronal mitochondrial trafficking, and disruption of this 
function can lead to axon degeneration (Baloh et al, 2007; Misko et al, 2012). 
Mitochondrial fission is mediated by Drp1.  Drp1 is mainly cytoplasmic and its 
translocation to mitochondria, recruited by Fis1 and/or Mff, is essential for 
mitochondrial fission. Drp1 is subjected to several posttranscriptional modifications, 
including phosphorylation, ubiquitination, SUMOylation and nitrosylation, which can 
either activate or repress fission activity (Cho et al, 2010; Oettinghaus et al, 2012).   
Although mitochondrial fission per se does not cause cell death, fragmentation of 
mitochondria has been shown to play a key role in cell death progression. Mitochondrial 
fragmentation occurs early in apoptosis and can be delayed by expressing a dominant 
negative Drp1 (Breckenridge et al, 2003; Frank et al, 2001).  Recently, Drp1 has also 
been implicated in the induction of necrosis (Wang et al, 2012). Mutations in Mfn2 are 
the most commonly identified cause of Charcot-Marie-Tooth type 2 (CMT2), a 
dominantly inherited disease characterized by degeneration of peripheral sensory and 
motor axons (Zuchner et al, 2004). Purkinje cells require Mfn2 but not Mfn1 for 
dendritic outgrowth, spine formation, and cell survival (Chen et al, 2007). 
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Mitochondrial fragmentation is an early event that occurs before the release of 
mitochondrial proteins and neurite degeneration in an in vivo animal model of stroke 
(Barsoum et al, 2006). Despite the importance of mitochondrial dynamics in cell death 
progression the exact mechanism that underlies the mitochondrial fragmentation in 
excitotoxicity is incompletely understood. In this study, we assessed how the proteins of 
the core mitochondrial fusion/fission machinery are regulated in excitotoxicity. We 
found that Mfn2 levels are reduced in both in-vitro and in-vivo models of excitotoxicity,  
via MEF2 degradation that, by acting on the Mfn2 promoter, regulates basal levels of 
Mfn2. Downregulation of Mfn2 causes mitochondrial dysfunction and altered Ca
2+
 



















Mfn2 protein expression is reduced in excitotoxicity 
Mitochondrial dynamics plays a pivotal role in cell death. Changes in mitochondrial 
morphology have been observed in excitotoxicity but the precise mechanism has not 
been fully defined. For a better understanding of the mechanism by which mitochondria 
are fragmented during excitotoxicity we exposed primary cortical cultures to moderate 
doses (30 M)  of the glutamate receptor agonist NMDA over a time course of 1, 2, 4 
and 8 hours and analyzed the expression of the proteins of the mitochondrial 
fission/fusion machinery. During the first 2 hours after NMDA application there were 
no significant changes in either fusion or fission proteins but after 4 hours of NMDA 
treatment we observed a 40% reduction in the fusion protein Mfn2 with no changes in 
the other fusion proteins, Mfn1 and Opa1. Surprisingly, Drp1 showed a tendency to 
reduce its protein levels (Fig. 1A, B). To rule out the possibility that changes in the 
expression of mitochondrial fission/fusion protein were due to changes in mitochondrial 
mass, volume normalization was also performed with the mitochondrial protein porin, 
achieving similar results (Fig. E1D). Using oxygen and glucose deprivation (OGD) as 
another in vitro model of excitotoxicity, we also found that the level of Mfn2 was 
reduced 4 hours after reoxigenation with no changes in the other proteins of the 
fission/fusion machinery (Fig. E1B and C). 
To check the pathophysiological relevance of these in vitro findings, we then used an in 
vivo model of cerebral ischemia in 12 days old rats consisting in applying a permanent 
middle cerebral artery occlusion combined with 90 minutes of transient occlusion of the 
ipsilateral common carotid artery (Vaslin et al, 2009).  During an ischemic episode, 
glutamate levels build up as a result of synaptic release and impaired and/or reversed 
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uptake mechanisms (Camacho & Massieu, 2006), which induces excessive activation of 
NMDA glutamate receptors (NMDARs) and Ca
2+
-mediated cell death (Arundine & 
Tymianski, 2003). We analyzed the expression of the mitochondrial fusion/fission 
machinery at several time points after the ischemic insult. The results were in the same 
trend to those found in vitro. Two hours after restoration of the common carotid artery 
blood flow, i.e. 3.5 hours after the ischemia onset, Mfn2 protein levels started to 
decline, and reached a significant 50% reduction 6 hours after the restoration of the 
common carotid artery blood flow (Fig. 1C,D and Fig. 1SD).  Drp1 also showed a slight 
but significant reduction (20%) 2 hours after the restoration of blood flow. Neither of 
the other mitochondrial fusion proteins (Mfn1 and Opa1) showed changes in levels 
during the 24 hours after the onset of ischemia. Thus, our in vitro neuronal cultures 
recapitulate well the excitotoxic in vivo model. 
 
Activation of Drp1 induces mitochondrial fragmentation 
We observed the downregulation of Mfn2 4 hours after initiating the insult, but 
nonetheless the kinetics of excitotoxicity-mediated mitochondrial fragmentation has 
been reported to be fast (Barsoum et al, 2006; Rintoul et al, 2003; Young et al, 2010). 
To clarify this, we analyzed the mitochondrial morphology of those neurons expressing 
RFP targeted to the mitochondrial matrix (mtRFP) that were still alive (as shown by 
nuclear DAPI staining; Fig. E2A) after NMDA treatment of different durations. 
Untreated neurons contained mainly well-connected tubular mitochondria (60%). After 
only 30–60 minutes of NMDA application most of the neurons contained globular 
mitochondria that remained intact for the following 2 hours with a small amount of 
additional fragmentation 4 hours after NMDA treatment (Fig. 2A and B). Although the 
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secondary fragmentation correlates with the diminished Mfn2 expression, it is unlikely 
that Mfn2 is responsible for the first and early phase of mitochondrial fragmentation.    
We observed a tendency for a decline in the level of Drp1 in excitotoxicity (Fig. 1). 
Nonetheless, what determines Drp1 activity is its subcellular localization. Drp1 is 
mainly cytosolic and by posttranslational modifications it is recruited to the 
mitochondria by Mff and/or Fis1 where it promotes fission (Gandre-Babbe & van der 
Bliek, 2008; James et al, 2003; Otera et al, 2010; Yoon et al, 2003). In basal conditions 
GFP-Drp1 transfected neurons showed a weak diffuse signal within the neuron. 
Application of NMDA for 1 hour produced a strong punctuate signal that co-localized 
with mitochondria (Fig. 2C). Overexpression of a mutant form of Drp1 (Drp1-K38A), 
which acts as a dominant negative (Smirnova et al, 1998), or using the Drp1 inhibitor 
mdivi-1, significantly attenuated the NMDA-mediated mitochondrial fragmentation 
during the first hour of NMDA treatment (Fig. 2D-E). Excessive calcium uptake by 
mitochondria in excitotoxicity causes mitochondrial depolarization (Nicholls, 2009; 
Soriano et al, 2006b), this produces an increase in cytosolic calcium that can activate 
calcineurin which has been shown to de-phosphorylate Drp1 to promote its recruitment 
to mitochondria and fission (Cereghetti et al, 2008). We analyzed whether 
mitochondrial fission preceded or was posterior to mitochondrial depolarization. We 
found that one minute before fission mitochondria have lost 60% of the mitochondrial 
membrane potential , which continues to dissipate progressively after fission (Fig. E2B 
and C). We next analyzed the possible involvement of calcineurin in the NMDA-
mediated mitochondrial fission. Inhibition of calcineurin with cyclosporine A (CsA) did 
not prevent mitochondrial fission (Fig. E2D) as neither did the inhibition of CaMK, a 
calcium dependent kinase that activates Drp1 (Han et al, 2008), with KN-62. Drp1 is 
also activated by nitrosylation (Cho et al, 2009). As it had been reported previously 
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(Barsoum et al, 2006; Cho et al, 2009), here we also showed that inhibition of the nitric 
oxide synthase with 7-Nitroindazole (7-Ni) blocked the mitochondrial fragmentation to 
the same extent as the mutant Drp1-K38A or mdivi-1 (Fig. 2E). These experiments 
indicate that NO-mediated Drp1 activation plays a key role in mitochondrial 
fragmentation during excitotoxicity, although other mechanisms may also be involved.  
 
 Mfn2 intervenes in an irreversible late phase of mitochondrial fragmentation 
Previous studies have shown that glutamate and nitric oxide mediated mitochondrial 
fragmentation are amenable to restoration once the stimulus has ceased (Barsoum et al, 
2006; Rintoul et al, 2003). Thereby, we decided to test the reversibility of mitochondrial 
morphology in our system.  We applied NMDA for 1 hour and then washed out the 
NMDA and returned to fresh media. We observed that the mitochondrial tubular 
morphology was recovered 90 minutes after replacing the media but that after 180 
minutes the mitochondria fragmented once again (Fig. 3A). The events that triggered 
the decline in Mfn2 levels began during the first hour of NMDA exposure since 
subsequent washout of the agonist did not block the reduction in Mfn2 (Fig. 3B).  
Because the delayed phase of mitochondrial fragmentation correlates with the reduction 
in Mfn2 protein levels (Fig. 1A, Fig. 2B and Fig. 3A, B) we reasoned that the reduction 
in Mfn2 levels in excitotoxicity intervenes in late mitochondrial fission.  We knocked 
down Mfn2 using shRNA, which targets its sequence (shMfn2).  Importantly, shMfn2 
reduced Mfn2 protein levels by around 50%, resembling the reduction observed in 
excitotoxicity (Fig. 3C).  As expected, knockdown of Mfn2 was sufficient to cause 
mitochondrial fragmentation (Fig. 3D). Another two shRNAs targeting Mfn2 at 
different sequences also showed mitochondrial fragmentation (Fig. E3A and B). 
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Conversely, exogenous expression of Mfn2 significantly blocked the late phase of 
mitochondrial fragmentation after NMDA washout (Fig. 3E and F). 
All of this indicates that excitotoxicity promotes mitochondrial fragmentation by at least 
two mechanisms, a fast mechanism relying on Drp1 activation that lasts while the insult 
is present, and a late mechanism dependent on the reduction in Mfn2 expression that 
takes place hours after the insult is generated and persists independently of the removal 
of the insult. 




In addition to its mitochondrial fusion activity, Mfn2 has unique properties which are 
not shared with Mfn1, such as activating mitochondrial oxidative metabolism or 
tethering of mitochondria with the ER regulating Ca
2+
 homeostasis  (Bach et al, 2003; 
Baloh et al, 2007; de Brito & Scorrano, 2008a; Pich et al, 2005). Since mitochondrial 
dysfunction and altered Ca
2+
 homeostasis are hallmarks of excitotoxicity we wondered 
how decreased levels of Mfn2 could affect mitochondrial function. Respirometric 
assays showed decreased respiratory control ratio (RCR) and spare respiratory capacity 
(SRC) in Mfn2 KD neurons (Fig. 4A, B). Determination of mitochondrial membrane 
potential showed that mitochondria in Mfn2 KD neurons had 15% lower mitochondrial 
membrane potential than control transfected cells (Fig. 4C), in concordance with what 
has been observed in other cell types (Bach et al, 2003; Soriano et al, 2006a). In 
agreement with lower SRC, when neurons were challenged with subtoxic doses of 
NMDA (15 M) mitochondrial membrane potential loss was greatly enhanced in Mfn2 
KD neurons (Fig. 4C). Concomitantly, when the culture medium was changed to a 
medium with pyruvate but without glucose just before the NMDA application (to rely 
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solely on mitochondrial metabolism) ATP levels decreased significantly in Mfn2 KD 
neurons (Fig 4D). All together these results indicate an impaired mitochondrial function 
in the Mfn2 KD neurons. 
Because mitochondria play a key role in buffering the increase in cytosolic Ca
2+
 
produced during excitotoxicity, which depends on proper mitochondrial membrane 
potential (Nicholls, 2009), we reasoned that Ca
2+
 homeostasis may be impaired in Mfn2 
KD neurons. Under basal conditions Mfn2 KD neurons have a slightly lower (9.9 
±3.52%) mitochondrial Ca
2+
 concentration than control neurons (Fig. 4E, F). The 
application of NMDA produced a lower increase of the mitochondrial Ca
2+
 in the Mfn2 
KD neurons than in the control neurons (Fig. 4E, F). Oppositely, the level of 
cytoplasmic Ca
2+ 
was moderately higher in the Mfn2 KD neurons and NMDA 
application produced a bigger increase in the Mfn2 KD neurons (Fig 4G, 4H, E4A). 
Because Rhod-2 localization to mitochondria is voltage sensitive and lower 
mitochondrial membrane potential could lead to reduced Rhod-2 fluorescence we also 
analyzed cytoplasmic Ca
2+





was moderately higher in Mfn2 KD neurons and NMDA application 
produced bigger increase in Mfn2 KD neurons (Fig 4G, 4H, E4A). Increase in 
cytoplasmic Ca
2+
 was due to reduced mitochondrial Ca
2+
 uptake since depolarization of 
mitochondria with CCCP, hence abolishment of mitochondrial Ca
2+
 uptake, produced 
the same increase in NMDA mediated rise in cytoplasmic Ca
2+
 in control or Mfn2 KD 
neurons (Fig. E4B).  
Together, these data support the notion that a reduction in Mfn2 causes mitochondrial 
malfunction, which causes disturbances in Ca
2+
 homeostasis. 
Mfn2 reduction intervenes in delayed excitotoxic death. 
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Given that reduced levels of Mfn2 had a great impact on mitochondrial membrane 
potential and Ca
2+
 handling when neurons were treated with low doses of NMDA, next 
we investigated whether the reduction in Mfn2 could have consequences for cell 
viability. We showed that this was indeed the case, as knockdown of Mfn2 sensitized 
neurons to subtoxic doses of NMDA (Fig. 5A). Another two shRNAs targeting Mfn2 at 
different sequences also showed sensitization to subtoxic doses of NMDA, ruling out 
the possibility of an off-target effect (Fig. E5A). Next, we overexpressed Mfn2 and 
observed an almost two fold protection to the NMDA-induced neuronal death (Fig. 
5B).The protection was not due to the restoration of mitochondrial morphology since 
overexpression of Mfn1 did not show significant protection to NMDA (Fig. E5B). 
Shortly after exposure to glutamate, a subpopulation of neurons died by necrosis. 
Surviving neurons can recover or transiently and undergo delayed cell death, depending 
on mitochondrial function (Ankarcrona et al, 1995; Luetjens et al, 2000).   We studied 
how exogenous expression of Mfn2 could affect the different phases of excitotoxic cell 
death. We determined cell death after an hour treatment with NMDA (30 M) followed 
by the wash out of NMDA and allowed the neurons to recover for different length of 
time.  After 1.5 hours recovery (i.e. 2.5 h from the onset of the insult), nearly 40% of 
the neurons died with no protection by Mfn2 expression. From then on, and correlating 
with endogenous Mfn2 reduction, cell death in the  neurons that were transfected with 
the control vector increased progressively but Mfn2 expression completely blocked the 
delayed cell death (Fig. 5C). 
Given that several mechanism are responsible for the NMDA-mediated cell death, to 
better characterize the mechanism by which reduction of Mfn2 causes delayed 
excitotoxicity we used NMDA at 15 M, which only causes death when Mfn2 is 
knocked down (Fig 5A). Analysis of the NAD
+
/NADH ratio as a readout of the 
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metabolic status of the neuron did not indicate that an energetic collapse was 
responsible for the neuronal death when Mfn2 expression was reduced (Fig. E5C). 
Evidences indicate that opening of the permeability transition pore (mPTP) and necrotic 
death occurs during the early phase of excitotoxicity as opposed to apoptosis that occurs 
in delayed excitotoxicity (Dirnagl et al, 1999). Consequently, inhibition of the mPTP 
with CsA failed to protect Mfn2 KD neurons to low doses of NMDA (15 M; Fig. 
E5D). During delayed excitotoxic cell death Bax translocates to mitochondria to 
produce the mitochondrial outer membrane permeabilization (MOMP) (D'Orsi et al, 
2012; Shelat et al, 2013; Xiang et al, 1998).  Bax is known to interact with Mfn2 
(Brooks et al, 2007; Karbowski et al, 2006) and Mfn2 interferes with Bax activation 
(Neuspiel et al, 2005; Sugioka et al, 2004). Bax siRNA blocked the NMDA-dependent 
neuronal death in Mfn2 KD neurons (Fig 5D).  In addition, overexpression of the anti-
apoptotic Bcl-xL protein also blocked the neuronal death (Fig. 5E). In agreement with 
the reported activation of calpain downstream of Bax activation (D'Orsi et al, 2012), by 
measuring cleavage of spectrin (calpain substrate) we observed an enhanced calpain 
activation in Mfn2 KD neurons (Fig. E5E). According to the role of Blc-2 family 
proteins regulating mitochondrial dynamics by using siBax and Bcl-xL overexpression 
partially prevented the delayed mitochondrial fragmentation after NMDA application 
(Fig. E5F, G).  
Next, we studied whether exogenous expression of Mfn2 affected Bax translocation to 
mitochondria in excitotoxicity. We observed that in GFP-Bax expressing neurons Bax 
was mainly cytoplasmic and that NMDA (30 M) application resulted in Bax 
translocation to mitochondria, forming the typical foci on the tips of the mitochondria 
(Karbowski et al, 2002; Yuan et al, 2006); Fig. 5F). Bax translocation to mitochondria 
was progressive after NMDA treatment and Mfn2 expressing neurons showed less 
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mitochondrial Bax than globin (control) expressing neurons (Fig. 5F, G). As expected, 
NMDA-mediated delayed cytochrome c release was blocked by Mfn2 expression in a 
similar pattern to mitochondrial Bax localization (Fig. 5H, I).   
All these data data indicate that the late reduction of Mfn2 levels impairs mitochondrial 
function and enhances delayed excitotoxic death by promoting Bax recruitment to 
mitochondria. 
 
Mfn2 is regulated at the transcriptional level in excitotoxicity 
Next we investigated the mechanism by which Mfn2 expression is reduced in 
excitotoxicity. It is well known that Mfn2 is degraded by the proteasome in a Parkin 
dependent manner (Chan et al, 2011; Tanaka et al, 2010). We wondered whether the 
decrease in Mfn2 levels in excitotoxicity was due to its proteasomal degradation. 
Surprisingly, we found that pretreatment of neurons with the proteasome inhibitor MG-
132 did not abolish the NMDA-dependent reduction in Mfn2 (Fig. 6A, B) even when 
the concentration of MG-132 used (10 M) promoted the accumulation of ubiquitinated 
proteins and effectively blocked the CCCP-mediated degradation of Mfn2 (Fig. E6A, 
B). Therefore we can conclude that excitotoxic dependent downregulation of Mfn2 is 
not dependent on proteasomal degradation.  
Excitotoxicity causes changes in transcriptional programs (Cook et al, 2012; Zhang et 
al, 2007), which could be consistent with the slow effect of NMDA on Mfn2 
expression. We investigated whether Mfn2 reduction was due to changes in its gene 
expression. Mfn2 gene expression showed an initial increase during the first hour after 
NMDA application, probably a defensive response to malfunctioning mitochondria. 
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Mfn2 gene expression started to decrease during the second hour, reaching a plateau 
after 4 hours that remained steady for up to 8 hours of treatment and correlated with the 
time course of protein expression (Fig. 6C).  Neurons subjected to OGD also showed 
downregulation of Mfn2 mRNA expression (Fig. E6C).The repression of Mfn2 
expression is specific since mitochondrial Mfn1 and cytoplasmic SESN2 expression 
were not affected by NMDA treatment (Fig. 6C). These data indicate that Mfn2 gene 
expression is downregulated during excitotoxicity, but do not rule out the possibility 
that other proteases could participate in the excitotoxicity mediated reduction in Mfn2. 
To verify that a transcriptional change is the main mechanism by which Mfn2 
expression is reduced in excitotoxicity, we used the transcriptional inhibitor 
actinomycin D or the translational inhibitor cycloheximide. As expected, the use of 
these inhibitors reduced Mfn2 protein levels but additional application of NMDA did 
not produce a further reduction in Mfn2, as would be expected if a proteolytic process 
was responsible for NMDA-mediated Mfn2 downregulation (Fig. 6 D, E). Thus, all 
these sets of experiments clearly indicate that the main mechanism by which NMDA 
mediates Mfn2 downregulation is at the transcriptional level rather than being a 
proteolytic process. 
 
Excitotoxicity mediated Mfn2 downregulation depends on MEF2  
ROS is an important regulator of cell signaling (Holmstrom & Finkel, 2014). We first 
examined whether mitochondrial ROS produced in excitotoxicity could mediate Mfn2 
downregulation. The use of general scavenger trolox, or apocynin, an inhibitor of 
NADPH oxidase, which is the major source of ROS in excitotoxicity (Brennan et al, 
2009), failed to block NMDA-mediated Mfn2 downregulation (Fig. E7A). 
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 MEF2(A–D) are transcription factors that play an important role in neuronal 
development and  viability (Flavell et al, 2008; Mao et al, 1999). During excitotoxicity 
MEF2s are cleaved by caspases generating DNA binding domains without the 
transactivation domain, which acts as a dominant negative interfering form (Li et al, 
2001; Okamoto et al, 2002). Time-course analysis of protein extracts of cortical neurons 
exposed to NMDA, subjected to OGD or brains from rats that have been subjected to 
ischemia showed a calcium dependent reduction of MEF2A in a pattern that correlated 
well with Mfn2 expression (Fig. 7A, B and Fig. E7B, C). This raises the possibility that 
NMDA-dependent cleavage of MEF2s may be responsible for Mfn2 downregulation in 
excitotoxicity. Neurons expressing the DNA binding domain of MEF2 without the 
transactivation domain (MEF2-DN) showed reduced expression of Mfn2 protein and 
mRNA (Fig. 7C).  Consistent with the reduced expression of Mfn2, MEF2-DN 
transduced neurons contained fragmented mitochondria whose morphology was 
restored by expressing exogenous Mfn2 (Fig. 7D, E). Mitochondria of MEF2-DN 
expressing neurons showed reduced mitochondrial membrane potential that could be 
raised by overexpression of Mfn2 (Fig. 7F). MEF2-DN expression caused neuronal 
death when doses of NMDA at the threshold of toxicity (15 M) were applied, but co-
expression of Mfn2 completely blocked neuronal death (Fig. 7G, H).  All these results 
demonstrate that Mfn2 expression is regulated by MEF2 but do not answer the question 
of whether MEF2 degradation is the main factor mediating Mfn2 downregulation in 
excitotoxicity. Thus, we analyzed the levels of Mfn2 mRNA in neurons transduced with 
AAV coding MEF2-DN and observed that Mfn2 downregulation with respect to its 
control (GFP transduced) neurons was not additively enhanced when NMDA was 
applied, suggesting that they act in a common pathway (Fig. 7C; note that the AAV 
transduction efficiency was around 75-90%, thus the results underestimate the actual 
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MEF2-DN-dependent repression). Together, these data demonstrate a crucial role of 
MEF2 in the excitotoxicity-dependent downregulation of Mfn2. 
 
MEF2A directly regulates basal Mfn2 expression in neurons 
Next, we investigated whether MEF2 could directly regulate Mfn2 expression. In 
promoter reporter assays, MEF2-DN repressed the activity of human Mfn2 promoter in 
neurons but did not repress the activity of SESN2 promoter, consistent with the 
unchanged expression of SESN2 in excitotoxicity (Fig. 8A).  The effect of MEF2-DN 
on the Mfn2 promoter was neuron specific since it did not affect the promoter activity in 
10T1/2 fibroblasts, a cell line with far less expression of MEF2A than neurons (Fig. 8A 
and Fig. E8A). These results are consistent with a prevalent role of MEF2 in the 
regulation of basal Mfn2 expression in neurons.  
Next we determined the cis-elements involved in the effects of MEF2A on the 
transcriptional activity of the Mfn2 promoter. In agreement with the low expression of 
MEF2A in 10T1/2 cells, over-expression of MEF2A strongly activated the Mfn2 
promoter (Fig. 8B). Deletion analysis of the Mfn2 promoter identified the MEF2A 
activated region as being between -1332 and -668 relative to the transcription start site 
(Fig. 8B). The MEF2 transcription factors bind DNA in A/T rich sequences (Black & 
Olson, 1998). The sequence -1332/-862 contains two putative MEF2 binding sites (Fig. 
E8B). In order to show the functional role of these putative MEF2 binding sites we 
disrupted the A/T rich sequence, introducing C and G by directed mutagenesis (Fig. 
E8B). Mutation of BOX 1 did not modify the MEF2A induced promoter activation but 
mutation of BOX 2 cancelled the effect of MEF2A (Fig. 8C). These results indicated 
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that BOX 2 is the cis-element required for MEF2A mediated activation of the Mfn2 
promoter.  
Since MEF2A was able to trans-activated the Mfn2 promoter, EMSA experiments were 
performed in order to ascertain whether MEF2A was bound to BOX 2. A DNA 
fragment encompassing BOX 2 was radioactively labeled, and incubated with nuclear 
extracts of HeLa cells overexpressing MEF2A. MEF2A bound BOX 2 containing 
probe, inducing the typical double band mobility shift (Santalucia et al, 2001), but did 
not bind the mutated probe (Fig. 8D). The retarded bands were competed with a 25- or 
100-fold excess of unlabeled oligonucleotide probe or 100-fold excess of a probe of the 
Glut4 promoter that has previously been shown to bind MEF2 (Santalucia et al, 2001), 
whereas the cold mutated probe was unable to compete with the retarded bands. In 
addition, an antibody against MEF2 supershifted the complex (Fig. 8E).  
Bioinformatic analysis of 2.5 kb of the rat Mfn2 promoter identified that there were four 
putative MEF2 binding sites in the region spanning -2313/-1983 (Fig. E8C). We 
designed primers to amplify within this region and performed ChIP with anti-MEF2A 
antibody in rat cortical neurons unstimulated or stimulated with NMDA for 4 hours. We 
found that under basal conditions MEF2A was bound to this region but after NMDA 
stimulation there was no enrichment of this region with the chromatin 
immunoprecipitate (Fig. 8F). These observations support the hypothesis that MEF2A 
regulates basal transcription of Mfn2 in neurons and as a consequence of MEF2A 







Mitochondria are dynamic organelles that continuously fuse and divide. Changes in 
mitochondrial dynamics have profound effects on mitochondrial function and therefore 
mitochondrial viability.  Here, we have studied mitochondrial dynamics in 
excitotoxicity. Our findings show that most of the mitochondrial fragmentation occurs 
within the first hour following the excitotoxic insult.  This early phase depends partially 
on Drp1mitochondrial translocation and lasts as long as the stimulus is present. Four 
hours after initiation of the insult, and regardless of its removal, delayed mitochondrial 
fragmentation that correlates with the reduction in Mfn2 protein levels due to its 
transcriptional downregulation occurs. Loss of Mfn2 impairs mitochondrial function 
and participates in delayed excitotoxic damage.  
Mechanisms of mitochondrial fragmentation in excitotoxicity 
Drp1 is subjected to several posttranslational modifications that regulate its fission 
activity. Neuronal depolarization activates CaMKI, which phosphorylates Drp1 at Ser 
600, promoting mitochondrial fragmentation that is reversible once neurons repolarize 
(Han et al, 2008). The reversibility of Drp1-mediated mitochondrial fragmentation has 
also been observed in pathological conditions.  Mitochondrial fragmentation induced by 
NO donors is a rapid and reversible process (Barsoum et al, 2006). Ca
2+
 influx through 
the NMDA receptor produces NOS activation, which has been implicated in nitrosative 
stress and cell death (Sattler et al, 1999). Nitrosative stress causes S-nitrosylation of 
Drp1 at Cys644, which enhances mitochondrial fission (Cho et al, 2009).  In agreement 
with previous reports (Barsoum et al, 2006), we show that NOS inhibition partially 
blocks NMDA-mediated mitochondrial fragmentation.  The degree of inhibition of the 
mitochondrial fragmentation achieved by NOS inhibitors is similar to that achieved 
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using genetic and pharmacological inhibitors of Drp1. That suggests the involvement of 
a mechanism other than Drp1 in the early phase of mitochondrial fragmentation. Opa1 
is cleaved in a mitochondrial membrane potential dependent manner, promoting 
mitochondrial fission (Griparic et al, 2007; Ishihara et al, 2006; Song et al, 2007), but 
we were unable to detect changes in the proportion of short and long forms of Opa1 in 
excitotoxicity, either in vitro or in vivo.  Another possibility is that excitotoxicity could 
promote the modification of lipids, which has been shown to affect mitochondrial 
dynamics (Choi et al, 2006). The possibility that as yet unknown posttranscriptional 
modifications inhibit the fusion machinery in excitotoxic conditions cannot be ruled out 
either.  
Our data also indicate that Mfn2 intervenes in the delayed phase of mitochondrial 
fragmentation. Cultured rat primary cortical neurons exposed to excitotoxic doses of 
NMDA or subjected to OGD, and in vivo middle cerebral artery occlusion in rats show 
reduced expression of Mfn2 but no changes in Mfn1 or Opa1. During the preparation of 
the manuscript two independent studies confirmed the downregulation of Mfn2 in 
excitotoxicity. Primary rat cortical neurons exposed to 3 hours of OGD also produced a 
reduction in Mfn2 protein with no changes in Opa1 and an increase in Mfn1 expression 
(Wappler et al, 2013). In an in vivo study, a reduction in Mfn2, and also of Opa1 
expression, was observed in mice subjected to MCAO (Kumari et al, 2012).  
 
Dependence of neurons on Mfn2 
Mfn1 can compensate for some but not all of the functions of Mfn2. Analysis of Mfn2 
and Mfn1 knockout mice indicates that they have both redundant and distinct functions 
(Chen et al, 2003; Chen et al, 2007). Unlike Mfn1, a lack of or defects in Mfn2 have a 
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great impact on neuronal viability. Mfn2 mutations have been found to cause the 
dominantly inherited neurological disease Charcot-Marie-Tooth type 2A (CMT2A) 
(Zuchner et al, 2004). Defects in mitochondrial mobility and fusion have been proposed 
as the mechanism by which Mfn2 mutations cause CMT2A but this has not been fully 
established (Baloh et al, 2007). Mfn2 is required for postnatal development of the 
cerebellum (Chen et al, 2007). Conditional dopaminergic Mfn2 knockout neurons show 
that Mfn2, but not Mfn1, is essential for striatal projections and proper nigrostriatal 
circuit function (Lee et al, 2012; Pham et al, 2012). 
As a consequence of excitotoxicity-mediated Ca
2+
 overload neurons die initially by 
necrosis, surviving neurons can undergo delayed death in a manner dependent on the 
mitochondrial function (Ankarcrona et al, 1995; D'Orsi et al, 2012; Luetjens et al, 
2000). We show here that, unlike Mfn1 expression, exogenous expression of Mfn2 
protects neurons against NMDA-induced cell death. Mfn2 expression interferes with 
Bax recruitment to mitochondria and subsequent release of cytochrome c, as has been 
observed in other cell types (Neuspiel et al, 2005; Sugioka et al, 2004). The precise 
mechanism by which Mfn2 interferes with Bax activation is unknown. One possibility 
is that loss of Mfn2 facilitates OMM remodeling by Drp1 that has been shown to 
stimulate Bax oligomerization (Montessuit et al, 2010). Mfn2 interacts with different 
members of the Bcl-2 family, both pro- and anti-apoptotic (Suen et al, 2008). It cannot 
be ruled out the possibility that by changing Mfn2 levels it affects the equilibrium of 
interactions between pro- and anti-apoptotic Bcl-2 proteins to favor Bax assembly and 
MOMP formation.   
The relation between autophagy and cell death is controversial (Baehrecke, 2005; 
Galluzzi et al, 2012). Although in most known cases autophagy constitutes a 
cytoprotective response activated by dying cells in an attempt to cope with stress 
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(Galluzzi et al, 2012), cell death with and by autophagy has been reported in focal 
cerebral ischemia (Puyal et al, 2013; Puyal et al, 2009). Mfn2 KO fibroblasts show 
reduced autophagy in response to ER stress (Muñoz et al, 2013). Interestingly, it has 
been reported that phosphorylated Mfn2 by PINK1 acts as a receptor for Parkin (Chen 
& Dorn, 2013) which is recruited to damaged mitochondria to promote mitophagy 
(Chen & Dorn, 2013; Narendra et al, 2008). How the reduction of Mfn2 in 
excitotoxicity affects mitophagy and autophagy-mediated cell death awaits further 
investigations.  
Mfn2 is transcriptionally downregulated in excitotoxicity 
During recent years several groups have established the role of the 
ubiquitin/proteasomal system in stress-mediated Mfn2 degradation. Mitochondrial 
depolarization promotes Mfn2 ubiquitinylation and proteasomal degradation in a 
Parkin-dependent manner (Chan et al, 2011; Tanaka et al, 2010). In stress conditions 
JNK phosphorylates Mfn2 at Ser 27 which recruits the E3 ubiquiting ligase Huwe 1, 
leading to its ubiquitination and degradation (Leboucher et al, 2012). Although 
excitotoxicity causes both mitochondrial depolarization and JNK activation (Borsello et 
al, 2003; Nicholls, 2009; Soriano et al, 2008; Soriano et al, 2006b), the reduction in 
Mfn2 protein levels was not blocked by inhibiting the proteasome. We found that the 
main mechanism implicated in Mfn2 reduction acts at the transcriptional level and does 
not seem to depend on enhanced proteolysis since inhibiting transcription or translation 
does not further reduce Mfn2 levels.  Interestingly, microarray analysis has showed 
more than 50% reduction in Mfn2 mRNA in the penumbra of rats subjected to MCAO 
(Ramos-Cejudo et al, 2012). We have shown that transcription factor MEF2 regulates 
basal Mfn2 transcription in neurons and that excitotoxicity-mediated MEF2 degradation 
(Li et al, 2001; Okamoto et al, 2002) results in transcriptional downregulation of Mfn2 
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(Fig. 8). MEF2 transcription factors play a pivotal role in brain development, synapse 
development and neuronal survival. The genetic program regulated by MEF2 that 
controls synaptic remodeling has been characterized (Flavell et al, 2008) but although 
many studies have pointed to the importance of MEF2 in supporting neuronal viability 
(Li et al, 2001; Mao et al, 1999; Okamoto et al, 2002), the precise target genes are 
poorly defined. Here we demonstrate that Mfn2 is a novel MEF2 target gene that can 
mediate its prosurvival function. 
 
Mitochondrial dynamics in neurodegeneration 
Mitochondrial dysfunction and excitotoxicity are common features of adult-onset 
neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s 
diseases, some of them occurring primarily in the absence of genetic linkage. 
Alterations in mitochondrial dynamics have been reported in all these diseases (Itoh et 
al, 2013). Mfn2 is dynamically regulated, thus its missregulation could intervene in the 
pathogenesis of neurodegenerative disorders. Further studies are required to clarify the 
role of Mfn2 in the progression of chronic late-onset neurodegenerative disorders. In 
this study we have shown that neurons with reduced Mfn2 have dysfunctional 
mitochondria, altered Ca
2+
 homeostasis that could sensitize neurons to additional 
insults. In our excitotoxicity model, Mfn2 expression protects against delayed 
exicitotoxic cell death by interfering with Bax recruitment to mitochondria. This 
suggests that Mfn2 downregulation could determine the fate of neurons in the penumbra 
area, the most clinically relevant therapeutic target against ischemic stroke (Lo, 2008). 
Thereby, Mfn2 is a potential therapeutic target against excitotoxicity in acute episodes 
and chronic neurodegenerative diseases.  
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Materials and methods 
Cell culture, transfection and determination of cell death 
 Cortical neurons from E21 Sprague Dawley rats were cultured as described previously 
(Soriano et al, 2008). Experiments were performed after a culturing period of 10–11 
days during which cortical neurons develop a rich network of processes, express 
functional NMDA-type and AMPA/kainate-type glutamate receptors, and form synaptic 
contacts. Prior to stimulations and transfections, neurons were transferred from growth 
medium to a medium containing 10% MEM (Invitrogen), 90% salt-glucose-glycine 
(SGG) medium (SGG: 114 mM NaCl, 0.219 % NaHCO3, 5.292 mM KCl, 1 mM 
MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM glycine, 30 mM glucose, 0.5 mM sodium 
pyruvate, 0.1% phenol red; osmolarity 325 mosm/l). Transfections were performed with 
Lipofectamine 2000 (Invitrogen). For cell death determination neurons transfected with 
GFP plus the indicated expression vectors were treated with NMDA for 6 hours and 
fixed. At this time point damaged neurons show pyknotic nuclei but GFP signal has not 
been lost yet. Nuclei were stained with DAPI and cell death was determined by 
counting the number of DAPI-stained pyknotic nuclei as a percentage of the total 
transfected neurons. NMDA-dependent cell death was calculated subtracting basal cell 
death to the cell death after NMDA treatment. 
10T1/2 and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum in subconfluent cultures. 
 Transfections were performed with either Lipofectamine 2000 (Invitrogen) or Fugene 
(Roche). For Bax knock down experiments 25 ng of Rat Bax (24887) siRNA-SMART 
pool (Thermo scientific) containing a pool of 4 siRNAs targeting rat Bax were 
transfected.    
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Focal ischemia model 
All animal procedures were authorized by the veterinary office of the Canton of Vaud 
and were in accordance with the directives of the Swiss Academy of Medical Science. 
After anesthesia (2.5% isoflurane), middle cerebral artery (MCA) occlusion  was 
performed in 12-day-old (P12) male Sprague-Dawley rats as previously described 
(Vaslin et al, 2009). Briefly, first, the main (cortical) branch of the left MCA was 
electrocoagulated just below its bifurcation into the parietal and frontal branches. Then, 
the left common carotid artery was transiently occluded with a clamp for 90 minutes. 
Rat pups were maintained at 37°C in the induction chamber (2.5% isoflurane) while the 
left common carotid artery was clamped. The arterial clamp was then removed and the 
rat pups were transferred back to their mother until sacrifice. 
Rat pups were decapitated and the brains were removed in PBS containing 1 mmol/L 
MgCl2 on ice. The cortex were dissected and collected in protein hypotonic lysis buffer 
(20 mmol/L HEPES, pH 7.4, 10 mmol/L NaCl, 3 mmol/L MgCl2, 2.5 mmol/L EGTA, 
0.1 mmol/L dithiothreitol, 50 mmol/L NaF, 1 mmol/L Na3VO4, 1% Triton X-100, and a 
protease inhibitor cocktail (Roche)). Tissues were homogenized and sonicated, and 
protein concentration was determined using the Bradford assay. 
Oxygen and Glucose deprivation.  
Neurons were transferred from TMo, washed once in a glucose-free, balanced salt 
solution (SGG): 114 mM NaCl, 0.219% NaHCO3, 5.292 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 10 mM HEPES, 1 mM glycine, 0.5 mM sodium pyruvate, 0.1% phenol red; 
which had previously been degassed by flushing the solution with 95% N
2
-5% CO2 for 
5 min. Cells were placed in degassed glucose-free SGG and put in a modular incubator 
chamber, which was flushed with 95% N
2
-5% CO2 for 4 min at a flow rate of 20 L/min, 
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according to manufacturer’s instructions (Stemcell technologies, Grenoble, France), in 
order to fully expel any remaining oxygen within the chamber. The chambered cells 
were then left in OGD at 37°C for 1 h, before being returned to normoxic conditions and 
glucose-containing media (TMo). No OGD control cells were placed in SGG and 
maintained in normoxic conditions for 1 h before also being returned to TMo. All cells 
were left in TMo until protein and RNA isolation for the time point indicated.  
Plasmids and virus generation 
The following plasmids have been described previously: the -1982/+45 Mfn2-
Luciferase vector and its 5’ deletion constructs (Sorianello et al, 2012), SESN2-Luc  
(Papadia et al, 2008), and mtRFP (Legros et al, 2002). HA-Mfn2 was subcloned into the 
pEF vector at the BamHI/XbaI sites.  The MEF2A expression vector was a gift from 
Pilar Ruiz-Lozano (Stanford University, USA), GFP-Drp1 was a gift from AM van der 
Bliek (UCLA, USA), Drp1-K38A-myc was Addgene plasmid 26049, deposited by Dr. 
Chan, and Mfn2-myc was Addgene plasmid 23213, deposited by Dr. Chan (Chen et al, 
2003)).  
The vectors used to construct and package recombinant adeno-associated viruses 
(rAAVs) were provided by Dr. Bading (U. Heidelberg, Germany (Zhang et al, 2007)). 
For construction of pAAV-MEF2-DN the first 252 bp of the mouse MEF2D cDNA (a 
gift from E. Olson; U. Texas South Western, USA) were amplified using the primers: 
forward 5’- ATA GGA TCC ATG GGG CGA AAG AAG ATA CAA ATC ACA CGC 
ATA ATG GAT G -3’ and reverse 5’- ATA AAG CTT TCA CAG ATC TTC TTC 
AGA AAT AAG TTT TTG TTA GGA GGG CCT CGT TTG AAA ATA AAA TC -
3’. The amplified product contains sequences that produce BamHI and HindIII 
restriction sites at the 5’ and 3’ respectively (italics) and also for inserting a myc tag 
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into the C terminus (bold). GFP in the rAAV-GFP vector was removed by 
BamHI/HindIII digestion and the MEF2-DN PCR product was cloned into the rAAV 
vector to express the first 84 amino acids of the N terminus of MEF2, which contains 
the DNA binding domain but not the transactivation domain. rAAV for shRNA 
expression contains the U6 promoter for shRNA expression and a CMV/chicken beta-
actin hybrid promoter driving hrGFP expression. rAAV-shRNA targeting Mfn2 were 
made by swapping the sh-sc sequence of rAAV-sh-sc (gift from H. Bading) for the 
following sequences of the rat Mfn2 into the BamHI and HindIII sites: shMfn2: 5’-
AGA GGG CCT TCA AGC GCC AGT-3’, shMfn2.2: 5’- GGG AAG AGC ACC GTG 
ATC AAT-3’, shMfn2.3: 5’- TCC TCA AGG TTT ATA AGA ATG-3’. All newly 
generated constructs were confirmed by sequencing.  
Neurons were infected with rAAV at DIV4. Infection efficiencies were determined at 
DIV 10-11 by analyzing GFP fluorescence or immunocytochemical analysis; they 
ranged from 80 to 90% of the viable neurons. 
Site-directed mutagenesis  
Site-directed mutagenesis was performed using the QuikChange
®
 Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions. The mutated 
sequences are shown in Fig. E8B. 
Luciferase assay 
Firefly luciferase-based reporter gene was transfected along with a Renilla expression 
vector (pTK-RL; Promega), and also, where relevant, MEF2-DN expression vector. 
Forty hours after transfection luciferase assays were performed using the Dual Glo 
assay kit (Promega) with Firefly luciferase-based reporter gene activity normalized to 
the Renilla control (pTK-RL plasmid) in all cases. 
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RNA isolation, RT-PCR and qPCR 
RNA was isolated using an RNA extraction kit (Life Technologies). For qPCR, cDNA 
was synthesized from RNA using the SuperScript® III First-Strand Synthesis SuperMix 
(Life Technologies) according to the manufacturer’s instructions. qPCR was performed 
in a StepOne Real-Time PCR System (Applied Biosystem) using GoTaq QPCR Master 
Mix (Promega) according to the manufacturer’s instructions. The primers used were: 
Mfn2 -F: 5’- ATG TCA AAG GGT ACC TGT CCA-3’, -R: 5’- CAA TCC CAG ATG 
GCA GAA CTT-3’;  SESN2 -F: 5’- GGA TTA TAC CTG GGA AGA CC -3, -R:  5’- 
CGC AGT GGA TGT AGT TCC -3’; Mfn1 –F: 5’-CAA ACT GCA GCC ACC AAG 
T-3’, -R: 5’- GTT GGC ACA GTC GAG CAA-3’; 18S -F: 5’-GTG GAG CGA TTT 
GTC TGG TT-3’, -R: 5’-CAA GCT TAT GAC CCG CAC TT-3’. Expression of the 
gene of interest was normalized to 18S, a commonly used control.  
Western blotting and antibodies 
Total cell lysates were boiled at 100°C for 5 min in 1.5x sample buffer (1.5 M Tris pH 
6.8; Glycerol 15%; SDS 3%; β-mercaptoethanol 7.5%; bromophenol blue 0.0375%). 
Gel electrophoresis was performed using 9% polyacrylamide gels. The gels were blotted 
onto PVDF membranes, which were then blocked for 1 hour at room temperature with 
5% (w/v) non-fat dried milk in PBS with 0.1% Tween 20. The membranes were then 
incubated at 4°C overnight with the primary antibodies diluted in blocking solution:  
anti-Mfn2 (1:2000; Abcam), Mfn1 (1:250, Santa Cruz), Opa1 (1:1000; BD 
Biosciences), Drp1 (1:1000, BD Biosciences), MEF2A (1:750, Santa Cruz), Jun 
(1:1000, BD Biosciences), Actin (1:10000, Sigma) and Porin (1:100000, Abcam).   For 
visualization of Western blots, HRP-based secondary antibodies were used followed by 
chemiluminescent detection on Kodak X-Omat film. Western blots were analyzed by 
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digitally scanning the blots, followed by densitometric analysis (ImageJ). All analyses 
involved normalizing to a loading control, Actin and Porin. 
 Imaging studies  
Cells were visualized using a TCS SP2 Leica confocal laser scanning microscope (Leica 
Lasertechnick GmbH, Mannheim, Germany) adapted to an inverted Leitz DMIRBE 
microscope at 37ºC in a controlled 5% CO2 atmosphere (Life Imaging Services). 
Pictures were acquired using a 63X (1.32 NA) Leitz Plan-Apochromatic objective. 
Images were analyzed using ImageJ software (Rasband, W.S., 1997-2012). 
To quantify mitochondrial membrane potential neurons were loaded with 20 nM 
tetramethylrhodamine methylester (TMRM; Sigma) in SGG medium without phenol 
red. Transfected cells were identified by co-transfecting GFP expression plasmid.   
Single cells were monitored, TMRM was excited at 540 nm and emission was measured 
using a 570 nm filter. The mitochondrial membrane potential was compared to that 
observed in surrounding untransfected neurons and subsequently expressed as a 
percentage of that observed in untransfected cells before NMDA stimulation. 
For mitochondrial Ca
2+
 analysis, neurons were loaded with 5 M Rhod-2 (Life 
Technologies) for 30 minutes at 4 ºC followed for extensive washout of the dye and 
incubation for 20 additional minutes with SGG without phenol red at 37 ºC. Single cell 




 was monitored with Fluo-4 (Life Technologies). Neurons were 
loaded 5 M Fluo-4 for 30 minutes at 37 ºC, after 2 washes with PBS were incubate for 
additional 15 minutes and excited at 488 nm and emission captured with a 516 filter. 
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For mitochondrial morphology analysis neurons were transfected with mitochondrially 
targeted RFP. After treatment neurons were fixed, and nuclei were stained with DAPI.  
The number of live neurons with tubular or fragmented mitochondria was counted. 
Drp1 or Bax localization was determined by transfecting cortical neurons with GFP-
Drp1 or Bax-GFP, respectively, and mtRFP. Forty-eight hours after transfection 
neurons were treated when appropriate with 30 M NMDA and fixed.  
For Cytochrome c inmunofluorescence, neurons were fixed with 4% parafolmaldehyde, 
permeabilized, blocked and incubated over night at 4 ºC with anti-cytochrome c 
antibody (Millipore). Antibody binding was visualized using biotinylated secondary 
antibody/Cy3-conjugated streptavidin. 
Measurement of cytoplasmic Ca
2+
 with Indo-1. 
AAV-sh-sc- or AAV-sh-Mfn2-transduced neurons were loaded with 5 M of the 
ratiometric Ca
2+
 indicator Indo-1 for 30 minutes at 37ºC in SGG medium without 
phenol red. After two washes with PBS neurons were incubated for 15 additional 
minutes in order to allow de-esterification of Indo-1. Measurements were made on 
Infinite M200PRO (TECAN). Neurons were excited at 350 nm and the ratio of the 
emitted fluorescence values at 405 (Indo-1 Ca
2+
 bound) and 485 nm (Indo-1 Ca2+ free) 




Thirty minutes before NMDA addition, neurons were incubated with medium without 
glucose and with pyruvate. After 30 minutes of NMDA treatment (15 M) ATP was 
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measured using the ATPlite Luminiscence Assay System (Perkin-Elmer) on Infinite 








NADH levels were measured individually taking advantage of the different 
stabilities of the different forms in acidic or basic buffer. We employed NAD
+
/NADH-
Glo assay (Promega) following manufacturer’s instructions. 
Oxygen consumption measurements. Cortical neurons were plated in SeaHorse 
Bioscience XF24 plates and transduced with AAV producing shRNA-scr or shRNA-
Mfn2. Seahorse Bioscience XF24 extracellular flux analyzer was used to measure 
oxygen consumption in these cells. The instrument was calibrated the day before the 
experiment, following the manufacturer’s instructions. On the day of the experiment, 
the injection ports on the sensor cartridge were loaded with 1.25 µM oligomycin (oli; 
complex V inhibitor) to distinguish the percentage of oxygen consumption devoted to 
ATP synthesis and the percentage of oxygen consumption needed to overcome the 
natural proton leak across the inner mitochondrial membrane, 3µM FCCP to calculate 
the "spare" respiratory capacity of cells, 1 µM rotenone (complex I inhibitor) and 1 µM 
antimycin A (complex III inhibitor) to calculate the remaining respiration due to 
residual oxygen consumption (rox). During the sensor calibration, neurons remained in 
a 37 °C incubator without CO2 in 700 μl of artificial cerebrospinal fluid (aCSF) assay 
medium (120 mMNaCl, 3.5 mMKCl, 1.3 mM CaCl2, 0.4 mM KH2PO4, 1 mM MgCl2, 
15 mM glucose, 1.0 mM pyruvate and 4 mg/ml fattyacid free bovine serum album, pH 
7.2.). Plates were immediately placed into the calibrated Seahorse XF24 flux analyzer 
for mitochondrial bioenergetic analysis. OCR was normalized for total protein/well and 
calculated as OCR – OCRroxto subtract non-mitochondrial respiration.  Spare respiratory 
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capacity was calculated as OCRCCCP/OCRrutine. Respiratory control ratio was calculated 
as OCRCCCP/OCRoli  
Chromatin immunoprecipitation (ChIP) 
Two 35 mm dishes were used for each treatment (approx 4.5 x 10
6
 cells). Medium was 
removed and treated cells were washed with pre-warmed medium and incubated for 10 
minutes at room temperature with 1% para-formaldehyde in pre-warmed medium, to 
crosslink proteins to DNA. The reaction was stopped by adding glycine to a final 
concentration of 125 mM for 5 min. Cells were washed twice with ice-cold PBS and 
harvested on ice in swelling buffer (25% HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.1% NP40 plus protease inhibitor cocktail set III (Calbiochem)). Nuclei were isolated 
using a douncer and centrifuging at 1500 g for 5 minutes. Nuclei were resuspended in 
200 µl sonication buffer (50 mM Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% 
Triton X100, 0.25% NaDeoxicolate, 0.1% SDS plus protease inhibitors). The nuclei 
were sonicated using a Diagenode Bioruptor (Liege, full power 30 s on, 30 s off, in an 
ice bath for 20 min) to produce fragments < 500 bp. Sonicated chromatin was 
precleared with protein-A agarose beads/salmon sperm DNA for 1 h at 4°C with 
agitation, beads were collected by centrifugation and supernatants were collected and 
subjected to immunoprecipitation. Eight micrograms of anti-MEF2A (Santa Cruz) or 
anti-Rabbit IgG (control, Sigma) was added for overnight incubation at 4ºC with 
agitation.  After chromatin immunoprecipitation, DNA was purified using Qiagen DNA 
purification columns. Input (1% of total immunoprecipitated) and immunoprecipitated 
DNA were subjected to qPCR analysis with primers amplifying the Mfn2 promoter (-
2204/-2136 of the rat Mfn2 promoter) 5’-TGG AGA TGG AAT TCA AGT TGG-3’ 
forward and 5’-TGGTCACAAAATGGCTCAGT-3’ reverse. As negative controls we 
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used primers for amplification of the actin gene 5’-AGC CAT GTA CGT AGC CAT 
CC-3’ forward and 5’-CTC TCA GCT GTG GTG GTG AA-3’ reverse. 
Electrophoretic mobility-shift assays  
HeLa cells were transfected with expression vector for MEF2A and 48 hours later, 
nuclear extracts were prepared as described previously (Santalucia et al, 2001). 
Radiolabeled double strand oligonucleotide probe containing the human Mfn2 promoter 
sequence (containing the MEF2 binding site: 5’-ATT TTT GTA TTT TTA GTA CAG-
3’ (MEF2wt), the mutated MEF2 binding site (in bold), which differs from the wild 
type in the same three nucleotides used in the luciferase assay: 5’-ATT TTT GGA TCC 
TTA GTA CAG-3’ (MEF2mut), and the MEF2 binding site in the Glut4 promoter: 5’- 
CGT GGG AGC TAA AAA TAG CCA-3’ (MEF2Glut4) was incubated with 10 μg 
nuclear extract in a final volume of 20 μl  and electrophoresis was performed as 
described previously (Santalucia et al, 2001). Dried gel was exposed to Kodak film. 
Competitor mutated oligonucleotide differed from wild-type EMSA sequence by the 
same base substitution used in the functional experiments. For supershift assays, MEF2 
antibody was added to the corresponding binding reactions after incubation with the 
radiolabeled probe, and incubated for a further 10 minutes at room temperature before 
loading onto gels. 
Statistical analysis 
Statistical testing involved two-tailed student T-tests. For any multiple comparisons 
within data sets we used a one-way ANOVA followed by the Bonferroni post-hoc test. 
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Figure 1. Mfn2 expression is reduced in excitotoxicity in vitro and in vivo. Western 
analysis of mitochondrial fusion/fission proteins. A) In vitro primary cortical neurons 
exposed to NMDA (30 M) for the indicated times and (B) densitometric analysis 
normalized to actin  (n=3–6).  C) In vivo brain extracts of rats subjected to MCAO plus 
90 minutes of ipsilateral common carotid artery clamp followed by clamp release for the 
indicated times and (D) densitometric analysis normalized to actin  (n=3–7). Mean ± 
s.e.m. in this and subsequent cases. *p<0.05 compared to control, two-tailed T-test.  
 
Figure 2. Activation of Drp1 induces mitochondrial fragmentation. A) 
Representative images of NMDA-induced mitochondrial fragmentation. Neurons 
transfected with mitochondria targeted RFP (mtRFP) were treated with NMDA (30 M) 
for the indicated times. Scale bar = 20 m. B) Mitochondrial morphology analysis from 
(A). (n=3-8). *p<0.05 compared to control, one-way ANOVA followed by Bonferroni 
post hoc test.  C) NMDA induces increased Drp1 translocation to mitochondria. 
Neurons were transfected with plasmids encoding GFP-Drp1 and mtRFP. After 48 h 
neurons were stimulated with NMDA (30 M) for 1 hour or left unstimulated, fixed and 
visualized under a confocal microscope. Brightness and contrast has been adjusted in 
the merged image to visualize GFP signal in the control condition. Scale bar yellow = 
20 m, white = 4 m. D) Representative images showing that genetic and 
pharmacological inhibitors of Drp1 block mitochondrial fragmentation.  Neurons were 
transfected with plasmids encoding mtRFP and Drp1-K38A or control (globin). After 
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48 hours neurons were stimulated with NMDA (30 M) for 1 hour or they were pre-
treated for 1 hour before NMDA stimulation with mdiv-1 (25 M) or 7-Nitroindazole 
((7-Ni) at 5 M in Arg free medium) and mitochondrial morphology was analyzed (E). 
(n=3). Scale bar = 20 m. *p<0.05, one-way ANOVA followed by Bonferroni post hoc 
test.  
Figure 3. Mfn2 intervenes in an irreversible delayed phase of mitochondrial 
fragmentation. A) Representative images and analysis of secondary mitochondrial 
fragmentation after NMDA wash-out. Neurons were transfected with mtRFP. After 48 h 
neurons were stimulated with NMDA (30 M) for 1 hour and washed out for the 
indicated times and mitochondrial morphology was analyzed (n=4–5). *p<0.05, one-
way ANOVA followed by Bonferroni post hoc test. Scale bar = 20 m. B) Mfn2 is 
reduced after NMDA wash-out. Western and densitometric analysis of neurons treated 
with NMDA (30 M) for 1 hour and washed out for 3 additional hours (n=4). *p<0.05, 
two-tailed T-test. C) Representative western blot and densitometric analysis of neurons 
transduced with AAV producing shRNA against Mfn2 or scrambled (n=4). *p<0.05, 
one-way ANOVA followed by Bonferroni post hoc test. D) Mfn2 knockdown causes 
mitochondrial fragmentation. Representative images  and analysis of mitochondrial 
morphology of neurons transfected with plasmids shMfn2 or sh-sc and mtRFP  (n=4). 
*p<0.05, two-tailed T-test. Scale bar = 20 m. E) Mfn2 blocks the delayed phase of 
NMDA-induced mitochondrial fragmentation. Representative images of neurons 
transfected with plasmids encoding mtRFP and Mfn2 or globin (CT) were treated with 
NMDA (30 M) for 1 hour and washed out for 3 additional hours and mitochondrial 
morphology was analyzed (F). (n=3). *p<0.05, one-way ANOVA followed by 




Figure 4 Mfn2 downregulation causes mitochondrial dysfunction and altered Ca
2+
 
homeostasis. A) Respiratory control ratio and (B) spare respiratory capacity of neurons 
transduced with AAV expressing shRNA targeting Mfn2 (sh-Mfn2) or scrambled (sh-
sc). (n=6) *p<0.05, two-tailed T-test. C) Loss of mitochondrial membrane potential in 
neurons transfected with sh-Mfn2 or sh-sc and treated with NMDA (15 M; arrow) was 
determined by measuring TMRM fluorescence. The values were normalized to 
surrounding untransfected neurons (n=19–21 neurons analyzed in five independent 
experiments). *p<0.05, two-tailed T-test. D) ATP levels were analyzed following 30 
minutes NMDA (15 M) treatment to neurons transduced with AAV producing sh-
Mfn2 or control sh-sc (in glucose free medium). (n= 4). *p<0.05, two-tailed T-test. E) 
Determination of mitochondrial Ca
2+
 with Rhodamine-2 in cortical neurons transfected 
with plasmids producing sh-Mfn2 or sh-sc and treated with NMDA (15 M), the values 
were normalized to the signal of surrounding untransfected neurons (n=20 neurons from 
5 independent experiments). F) Histograms show the average mitochondrial Ca
2+
 levels 
before and after NMDA application (15 M). *p<0.05, one-way ANOVA followed by 
Bonferroni post hoc test. G) Determination of intracellular Ca
2+
 with Fluo-4 in cortical 
neurons transfected with plasmids producing sh-Mfn2 or sh-sc and treated with NMDA 
(15 M), the values were normalized to the signal of surrounding untransfected neurons 
(n=16 neurons from 4 independent experiments). H) Histograms show the average 
intracellular Ca
2+
 levels before and after NMDA application (15 M). *p<0.05, one-
way ANOVA followed by Bonferroni post hoc test.  
Figure 5. Mfn2 reduction intervenes in delayed excitotoxic death.A) Neurons 
transfected with plasmids expressing sh-Mfn2 or sh-sc were treated with subtoxic doses 
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of NMDA (15 M) for 6 hours. Death was analyzed by fixing cells, DAPI-staining and 
counting pyknotic nuclei of the transfected neurons (n=5). *p<0.05, two-tailed T-test. 
B) Analysis and representative images of cortical neurons transfected with plasmids 
expressing Mfn2 or control (globin). After 48 h neurons were exposed to NMDA (30 
M) for 6 hours. NMDA dependent neuronal death was analyzed (n=8).  *p<0.05,two-
tailed T-test. Arrowhead points to the transfected neuron. Scale bar = 20 m. C) 
Cortical neurons expressing Mfn2 or control plasmid (globin) were treated with 30 M 
NMDA for 1 hour followed for extensive washout and allowed to recover for the 
indicated times. Cell death was analyzed by fixing cells, DAPI-staining and counting 
pyknotic nuclei of the transfected neurons (n=5). *p<0.05, one-way ANOVA followed 
by Bonferroni post hoc test. Representative images and cell death analysis of neurons 
transfected with a plasmid producing sh-Mfn2 plus (D) siRNA CT or targeting Bax, or 
(E) plasmid control or expressing Bcl-xL  and treated with NMDA (15 M) for 6 hour. 
(n=8). *p<0.05, two-tailed T-test. Arrowhead points to the transfected neuron. Scale bar 
= 20 m. F) Representative images of neurons expressing GFP-Bax and mtRFP plus 
control or Mfn2 expression vector and treated with NMDA (30 M) for 1 hour followed 
for extensive washout and allowed to recover for the 3 hours. Scale bar = 10 m. G) 
Analysis of mitochondrial Bax localization of neurons transfected as in (F) and allowed 
to recover after NMDA treatment (30 M) for the indicated times. (n= 3-5). *p<0.05, 
one-way ANOVA followed by Bonferroni post hoc test. H) Cytochrome c 
inmunofluorescence of neurons transfected with GFP plus control or Mfn2 expressing 
plasmid and treated as in (G). Arrowhead points to the transfected neuron, asterisk 
highlight cells with diffuse or lost cytochrome c. Scale bar = 20 m. I) Analysis of data 




Figure 6. Mfn2 is regulated at transcriptional level in excitotoxicity. Cortical 
neurons with or without pre-incubation with proteasome inhibitor MG-132 (10 M) 
were treated for 4 hours with NMDA (30 M) and Mfn2 levels were analyzed by 
western blot. A) Representative western and B) densitometric analysis (n=7). *p<0.05, 
one-way ANOVA followed by Bonferroni post hoc test. C) Cortical neurons were 
treated with NMDA (30 M) for the indicated times and mRNA expression was 
determined by real time qPCR.   (n=4). *p<0.05, two-tailed T-test. Cortical neurons 
were treated with transcriptional inhibitor actinomycin D, translational inhibitor 
cycloheximide and NMDA (30 M) for 4 hours as indicated and Mfn2 protein 
expression was analyzed by western blot. D) Representative western and E) 
densitometric analysis (n=4). *p<0.05, two-tailed T-test. 
 
Figure 7. Excitotoxicity-mediated Mfn2 downregulation depends on MEF2. Time 
course of excitotoxicity dependent MEF degradation (A) in cortical neurons in vitro 
treated with NMDA (30 M) for 4 hours and (B) brain extracts of rats subjected to 
MCAO plus 90 minutes of ipsilateral common carotid artery clamp followed by clamp 
release for the indicated times. C) Cortical neurons transduced with AAV expressing 
MEF2-DN or GFP (control) were treated with NMDA (30 M) for 4 hours and Mfn2 
mRNA and protein expression was determined (n=5). *p<0.05, one-way ANOVA 
followed by Bonferroni post hoc test. D) Mitochondrial morphology in cortical neurons 
transfected with the indicated expression vectors (n=4–5). *p<0.05, one-way ANOVA 
followed by Bonferroni post hoc test.  E) Representative images from (D). F) 
Mitochondrial membrane potential of neurons expressing the indicated vectors relative 
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to surrounding untransfected neurons (n=9-10 cells from three independent 
experiments). *p<0.05, two-tailed T-test. G) Cortical neurons were transfected with the 
indicated expression vectors. After 48 h were treated with subtoxic doses of NMDA (15 
M) for 6 hours and cell death was analyzed. (n= 8) *p<0.05, one-way ANOVA 
followed by Bonferroni post hoc test. H) Representative images from (G). Arrowhead 
points to the transfected neuron. Scale bar = 20 m. 
 
Figure 8. MEF2A directly regulates basal Mfn2 expression in neurons. A) 
Luciferase-based reporter of Mfn2 promoter in cortical neurons (left) or 10T1/2 cell line 
(right) and SESN2 promoter in cortical neurons (center) in control or over-expressing 
MEF2-DN (n=3-9). *p<0.05 compared to control, two-tailed T-test. B) Deletion 
analysis of a luciferase-based reporter of the Mfn2 promoter in 10T1/2 cells co-
expressed with control or MEF2 plasmids (n=3). *p<0.05, two-tailed T-test. C) Effect 
of putative MEF2 binding site mutations on MEF2-dependent induction of the Mfn2 
promoter in 10T1/2 cells  (n=3). *p<0.05 compared to control, two-tailed T-test. D) 
EMSA performed with nuclear extracts of HeLa cells overexpressing MEF2 and 
radiolabeled probe encoding BOX 2 from Mfn2 promoter. Retardation complexes are 
indicated with arrows. Excess of cold oligonucleotide, mutated oligonucleotide or 
oligonucleotide of the Glut4 gene that contains a MEF2 binding site was used to 
compete. Radiolabeled probe containing mutated BOX 2 did not produce retardation 
complexes. E) Supershift was performed using MEF2 polyclonal antibody. Pre-immune 
serum was used as a negative control.* indicates nonspecific binding of the probe to 
MEF2 antibody. F) ChIP on cortical neurons untreated or treated with NMDA (30 M) 
50 
 
for 4 hours using the indicated antibodies (n=4). *p<0.05, one-way ANOVA followed 
by Bonferroni post hoc test.  
 
Figure 9.  Proposed model for the changes in mitochondrial morphology and 
vulnerability in excitotoxic conditions. Under physiological conditions MEF2 binds 
Mfn2 promoter and regulates its basal gene expression resulting in mainly tubular 
mitochondria. In excitotoxic conditions Drp1 translocates to mitochondria and mediates 
rapid, reversible mitochondrial fission. An increase in cytosolic Ca
2+
 produces MEF2 
degradation and Mfn2 gene expression is consequently downregulated, producing a 
delayed long term effect on mitochondrial morphology. Reduced expression of Mfn2 
impairs mitochondrial function, which causes dysregulation of Ca
2+
 homeostasis, 
facilitates Bax translocation to mitochondria, release of cytochrome c and enhances 
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